ADMA Biologics, Inc. (ADMA) announced on Monday a projected revenue for fiscal year 2024, estimating figures between $417 million and $425 million. This marks an increase from the earlier guidance of $415 million. Analysts, on average, have predicted the revenue to stand at $423.19 million for this period.
For 2025, the company anticipates revenues exceeding $485 million. The net income for the year is projected to surpass $170 million, with adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) expected to be over $220 million.
Moreover, ADMA Biologics aims to achieve more than $1 billion in annual revenue by 2030.
